Enzo Biochem Inc., of Farmingdale N.Y., appointed Irwin Gerson to its board.
Illumina Inc., of San Diego, elected Scott Greer to its board.
Immunex Corp., of Seattle, promoted Philip Laub to vice president of human resources.
International Wex Technologies Inc., of Vancouver, British Columbia, added Anh Ho as chief scientific officer.
Isis Pharmaceuticals Inc., of Carlsbad, Calif., added Richard Brown as president of the company¿s genomics division, GeneTrove.
La Jolla Pharmaceutical Co., of San Diego, added William Ringo to its board.
Millennium Pharmaceuticals Inc., of Cambridge, Mass., appointed Kevin Starr executive vice president, business operations, and Bob Tepper was promoted to chief scientific officer and executive vice president, discovery. Starr also serves as chief financial officer.
Morphochem AG, of Munich, Germany, appointed Werner Schiebler head of business development.
NeoRx Corp., of Seattle, added Wolfgang Oster as chief operating officer.
Novasite Pharmaceuticals Inc., of San Diego, added Krzysztof Palczewski as the head of its crystallography group.
Penwest Pharmaceuticals Co., of Patterson, N.J., added William Wardell and Ralph D¿Agostino to its scientific advisory board.
Pheromone Sciences Corp., of Toronto, appointed Larry Cooper chief financial officer.
Prana Biotechnology Ltd., of Melbourne, Australia, added Guy Krippner as senior research scientist.
Proteome Sciences plc, of Cobham, UK, added G|nter Schmidt to its board.
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., elected George Yancopoulos to its board.
Response Biomedical Corp., of Vancouver, British Columbia, appointed Magnus Ohman to its scientific advisory board.